Published in Circ Cardiovasc Qual Outcomes on December 07, 2010
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ (2012) 1.61
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14
Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke (2012) 1.10
New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke (2014) 1.00
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail (2016) 0.88
Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology (2014) 0.83
Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep (2016) 0.82
MRI screening for chronic anticoagulation in atrial fibrillation. Front Neurol (2013) 0.82
Comparison of Atrial Fibrillation Guidelines. J Gen Intern Med (2015) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Stroke and anticoagulation in heart failure without atrial fibrillation: from risk to opportunity. Circulation (2015) 0.79
Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Curr Med Res Opin (2015) 0.79
Quality of stroke prevention care in atrial fibrillation: many moving targets. Circ Cardiovasc Qual Outcomes (2011) 0.76
Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)? J Am Heart Assoc (2016) 0.75
Rating the preferences for potential harms of treatments for cardiovascular disease: a survey of community-dwelling adults. Med Decis Making (2013) 0.75
Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75
Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther (2016) 0.75
Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. J Am Geriatr Soc (2016) 0.75
Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. Arrhythm Electrophysiol Rev (2016) 0.75
Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Mol Med (2017) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med (1994) 10.26
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74
Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet (2004) 7.33
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation (2004) 4.45
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med (2004) 3.63
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol (1995) 3.60
Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke (2002) 3.43
Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med (1994) 3.33
Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med (2000) 3.23
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med (1992) 2.67
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology (2000) 2.59
The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med (1996) 2.50
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med (1996) 2.50
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology (2007) 2.13
Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke (1995) 2.08
The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med (1997) 1.93
Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology (2002) 1.82
Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med (1992) 1.80
Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke (2006) 1.76
Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke (2005) 1.65
The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol (1984) 1.63
Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc (2006) 1.51
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke (2003) 1.50
Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med (2005) 1.42
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology (2008) 1.24
Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol (2006) 1.21
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke (2005) 1.20
Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology (2003) 1.17
Current status of stroke risk stratification in patients with atrial fibrillation. Stroke (2009) 1.13
Risk of hemorrhagic stroke with aspirin use: an update. Stroke (2005) 1.06
Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J (2007) 1.02
Subdural hematoma and oral anticoagulant therapy. Arch Neurol (1982) 0.98
Prognosis for survival after an initial stroke. Stroke (1995) 0.84
Stroke severity in patients with atrial fibrillation. Am J Med (2002) 0.84
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature (2007) 8.03
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA (2003) 4.13
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med (2002) 3.78
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Long-term outcomes of surgical and nonsurgical management of lumbar spinal stenosis: 8 to 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.67
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med (2013) 3.67
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med (2004) 3.63
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med (2007) 3.61
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Long-term outcomes of surgical and nonsurgical management of sciatica secondary to a lumbar disc herniation: 10 year results from the maine lumbar spine study. Spine (Phila Pa 1976) (2005) 3.17
Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 3.12
Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med (2002) 3.06
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis (2006) 2.96
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA (2002) 2.94
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke (2004) 2.92
Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol (2005) 2.85
Cerebral amyloid angiopathy in the elderly. Ann Neurol (2011) 2.84
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol (2010) 2.76
Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke (2008) 2.72
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59
Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol (2009) 2.55
Disconnection of the ascending arousal system in traumatic coma. J Neuropathol Exp Neurol (2013) 2.38
The unmet health care needs of homeless adults: a national study. Am J Public Health (2010) 2.36
Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke (2008) 2.34
Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol (2010) 2.31
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Cerebral microinfarcts: the invisible lesions. Lancet Neurol (2012) 2.31
Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol (2013) 2.29
Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol (2013) 2.29
Confounding by indication in retrospective studies of intracerebral hemorrhage: antiepileptic treatment and mortality. Neurocrit Care (2012) 2.25
Amyloid angiopathy-related vascular cognitive impairment. Stroke (2004) 2.21
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med (2002) 2.19
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation (2009) 2.18
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm (2006) 2.13
Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke (2008) 2.12
Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med (2004) 2.06
Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care (2003) 2.00
Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol (2004) 1.95
National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med (2004) 1.92
The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol (2006) 1.91
Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation (2010) 1.90
Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage. Stroke (2012) 1.89
Beta-amyloid, blood vessels, and brain function. Stroke (2009) 1.89
The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors. Stroke (2009) 1.89
Estimating cerebral microinfarct burden from autopsy samples. Neurology (2013) 1.87
Are patients more likely to see physicians of the same sex? Recent national trends in primary care medicine. Am J Med (2004) 1.87
A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). Diabetes Care (2004) 1.85
Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology (2014) 1.85
Microbleeds versus macrobleeds: evidence for distinct entities. Stroke (2009) 1.83
Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke (2005) 1.83
Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet (2012) 1.81
Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke (2009) 1.81
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med (2002) 1.78
Cerebral amyloid angiopathy: a systematic review. J Clin Neurol (2011) 1.77
Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol (2008) 1.74
Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol (2010) 1.74
The effect of survival bias on case-control genetic association studies of highly lethal diseases. Circ Cardiovasc Genet (2011) 1.71
Performance of the St. Jude Medical Riata leads. Heart Rhythm (2008) 1.71
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66
Protecting an endangered species: training physicians to conduct clinical research. Acad Med (2009) 1.66
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation (2005) 1.66
Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One (2010) 1.65